stockrow
Friday 6 November 2026
Export COGT’s income statement to Excel — free account
Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
31.60
2.02
+6.83%
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) EV/EBITDA
Cogent Biosciences, Inc. has no meaningful EV/EBITDA: its trailing twelve-month EBITDA is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 1.9× (March 2021) — the current reading is the lowest in ten years.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2020 | 1.4× | 293.18% |
| FY2019 | 0.4× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2020 | 0.0× | — |
| Jun 2020 | 0.2× | (69.85%) |
| Mar 2020 | 0.5× | 46.16% |
| Dec 2019 | 0.4× | (49.67%) |
| 11 more quarters | Free account |
Against its own ten years
Low 0.0×
High 1.9×
Ten-year median
0.0×
Current reading's percentile
88
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| ERAS Erasca, Inc. compare | n/m |
| TVTX Travere Therapeutics, Inc. compare | n/m |
| DNTH Dianthus Therapeutics, Inc. compare | n/m |
| SRRK Scholar Rock Holding Corporation compare | n/m |
| MANE Veradermics Incorporated compare | n/m |
| CRSP CRISPR Therapeutics AG compare | n/m |
| COGT Cogent Biosciences, Inc. | n/m |
| KOD Kodiak Sciences Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | 32.2× |
| Biotechnology industry median | 0.7× |
| Healthcare sector median | 8.5× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on COGT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement